Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
Crossref DOI link: https://doi.org/10.1186/s12879-017-2414-9
Published Online: 2017-05-02
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Popejoy, Myra W.
Long, Jianmin
Huntington, Jennifer A.
Funding for this research was provided by:
Merck (US)
